AUNA heads into its Q1 2026 earnings report today having already delivered its first numbers — and the picture is mixed.
The headline tells two stories at once. Revenue of $337M beat the $318M estimate by roughly 6%, a solid beat for a multi-market Latin American healthcare operator. But adjusted EPS of $0.05 badly missed the $0.19 consensus — a gap that implies meaningful margin pressure beneath the revenue line. The EPS shortfall ranks in just the 2nd percentile on ORTEX's surprise factor, underlining how far the bottom line fell from expectations.
That margin story has shadowed the stock for weeks. AUNA fell 15% over the past month to $4.75, with further losses of 3% on the week and 2% on the session. The sell-off reflects a stock trading well below where analysts modelled it — the consensus mean target is $7.13, implying roughly 50% upside from current levels. Valuation metrics remain compressed: P/E of 4.9x and EV/EBITDA near 4.9x put the stock trading at a fraction of book. The forward earnings growth factor ranks in the 94th percentile, meaning the market is pricing in a lot of near-term disappointment relative to the longer-run earnings trajectory.
The analyst backdrop captures the tension cleanly. JP Morgan downgraded AUNA to Neutral in November 2025, halving its price target from $13.50 to $6.00 — a call that now looks prescient given the stock has continued to slide. Jefferies initiated at Buy with a $9.00 target in January 2026, pointing to the structural growth opportunity across Colombia, Peru, and Mexico. That $6–$9 target range from active coverage still sits well above where the stock trades, but the JP Morgan move to the sidelines signals concern about near-term execution rather than the long-term thesis.
The short interest picture does not aggravate the setup. At 2.2% of free float — up 14% on the week but still modest in absolute terms — short positioning is far from crowded. Borrowing is cheap at 1.3% cost to borrow, and availability is extremely loose at over 1,300% of short interest, meaning there is no meaningful constraint on new short positions. That combination suggests the recent price weakness is more about fundamental disappointment than an aggressive short campaign. Ownership remains concentrated: Enfoca holds 43% of shares, which limits the free float and likely dampens volatility in either direction.
Today's full release will test whether the revenue strength can translate into a credible margin recovery path — and whether management can explain the EPS miss in a way that restores confidence in the forward earnings estimates the market had been pricing.
See the live data behind this article on ORTEX.
Open AUNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
